

# Investor Relations



## Newron Pharmaceuticals SpA: Expanding Global and U.S. Investor & Partner Visibility



### THE CHANGE THEY WANTED

- ✓ Newron is a Swiss-traded biopharmaceutical company focused on therapies for patients with diseases of the central nervous system.
- ✓ Promote new **breakthrough data** supporting that evenamide for schizophrenia impacts **long-term brain plasticity** changes in its long-term therapeutic actions.
- ✓ Build **global visibility** and expand understanding with sell-side analysts, potential partners/licensees, investors, and the investment banking community.

### WHAT WE DID

- ✓ Execute a **globally viewed** scientific and investor-oriented R&D Day to increase investor and partner visibility.
- ✓ Develop a **US-centric marketing strategy** for the event, including message and presentation development, event and location branding, and broadcast.
- ✓ Audience acquisition through **extensive media relations**, press release distribution, focused email campaigns, and personal investor and partner outreach.

### THE CHANGE WE DELIVERED

- ✓ Secured the participation of the **world's leading experts** in neurobiology, psychiatry, and schizophrenia as speakers.
- ✓ Live video of three **leading schizophrenia KOL experts**, elevating Newron's presence and market shaping
- ✓ **35 in-person attendees**, including representatives from 5 investment banks and 9 sell-side analysts.
- ✓ More than 200 live webcast participants from 7 countries worldwide.
- ✓ **Global webcast** of event listened to for more than **700 total hours** in more than 400 live and on-demand sessions



# Strategic Market Shaping Event



**Evenamide ROADMAP TO REGISTRATION 2024 Investor Day**

**MEET THE PRESENTERS**

**Stefan Weber, CEO**, was appointed Chief Executive Officer and Executive Director of Newron in 2022, having previously served as CEO from 2015. He received the 2023 award for leading the company through a period of significant growth and operational excellence. Stefan has been instrumental in securing various substantial funding transactions, including M&A, equity and debt financings, and has been instrumental in the company's strategic growth and expansion.

**Ravi Arora, M.D.**, has been Newron's Chief Medical Officer since 2020. For over 20 years, he has been responsible for the conduct of clinical trials. He has received and been involved in over 10 international non-IRB applications, and over 7 international IRB applications. He has published extensively, including over 100 papers and 200 abstracts, posters and presentations.

**Anthony Green, Ph.D.**, is the Distinguished Professor of Neuroscience, and Professor of Psychiatry and Psychology at the University of Michigan. Dr. Green is a recipient of the award for his research in the field of schizophrenia, and his research has led to the development of novel therapies for schizophrenia. He is also a recipient of the award for his research in the field of schizophrenia, and his research has led to the development of novel therapies for schizophrenia.

**Julie Kiser, M.D.**, is a Co-Director & Professor, Institute of Behavioral Sciences, and a Senior Lecturer at Harvard Medical School. She is also a recipient of the award for her research in the field of schizophrenia, and her research has led to the development of novel therapies for schizophrenia. She is also a recipient of the award for her research in the field of schizophrenia, and her research has led to the development of novel therapies for schizophrenia.

**Stephen R. Marder, M.D.**, is the David L. Freeman Professor of Psychiatry at the School of Medicine at Johns Hopkins. He is also a recipient of the award for his research in the field of schizophrenia, and his research has led to the development of novel therapies for schizophrenia. He is also a recipient of the award for his research in the field of schizophrenia, and his research has led to the development of novel therapies for schizophrenia.

**Agenda**

- 9:00 am Introduction and overview of the day's agenda - **Stefan Weber, CEO**
- 9:10 am Introduction to evenamide and CNS target space - **Ravi Arora, M.D.**
- 9:30 am "Evenamide can exert unique effects in schizophrenia by targeting the role of pathology-associated immune system" - **Anthony Green, Ph.D.**
- 9:35 am "Effort to treat poorly responding patients with schizophrenia, and other results with evenamide (give me hope for these patients)" - **Julie Kiser, M.D.**
- 10:00 am "New Hope for Patients with Treatment-Resistant Schizophrenia: Clinical Results with Evenamide" - **Stephen R. Marder, M.D.**
- 10:25 am Newron's registration and development program for evenamide in the U.S. and Europe for Schizophrenia treatment - **Ravi Arora, M.D.**
- 10:40 am U.S. & Europe and the market - **Stefan Weber, CEO**
- 10:55 am Closing remarks - **Stefan Weber, CEO**

**Evenamide ROADMAP TO REGISTRATION**

**JUNE 25 Newron Pharmaceuticals 2024 Investor Day**

**Investors**

Keep track of our business

This area contains investment and shareholder information

**Webcast Results**

Total views:	435
Total concurrent views:	211
Total minutes viewed:	42,720
Average watch time:	53 min.

